Pramipexole in treatment-resistant depression: A 16-week naturalistic study

Bipolar Disorders

Volumn 4, Issue 5, 2002, Pages 307-314

  Lattanzi, Lorenzo ^a   Dell'Osso, Liliana ^a   Cassano, Paolo ^a   Pini, Stefano ^a   Rucci, Paola ^a   Houck, Patricia R ^b   Gemignani, Alfredo ^a   Battistini, Giulia ^a   Bassi, Annalisa ^a   Abelli, Marianna ^a   Cassano, Giovanni B ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Augmentation strategy; Bipolar depression; Pramipexole; Treatment resistant depression

Indexed keywords

AMANTADINE; AMISULPRIDE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; LITHIUM; MIANSERIN; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PERGOLIDE; PRAMIPEXOLE; REBOXETINE; ROXINDOLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; TOPIRAMATE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; ATAXIA; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CLONUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HUMAN; HYPOMANIA; HYPOTENSION; INSOMNIA; MALE; NAUSEA; PRIORITY JOURNAL; RATING SCALE; RESTLESSNESS; SYMPTOMATOLOGY; TREMOR;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZOTHIAZOLES; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; THIAZOLES;

EID: 18644369579     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2002.01171.x     Document Type: Article

References (27)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 179-200.
2. Fawcett J, Barkin RL. Efficacy issues with antidepressants. J Clin Psychiatry 1997; 58: 32-39.
3. Roose SP, Glassman AH, Walsh BT, Woodring S. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry 1986; 143: 345-348.
4. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19: 427-434.
5. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A Meta-Anal Arch General Psychiatry 1996; 53: 842-848.
6. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000; 61: 26-32.
7. Bouckoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull 1993; 29: 207-211.
8. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry 1999; 32: 47-55.
9. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; 12:S7-SI4.
10. Szegedi A, Hilibert A, Wetzel H, Klieser E, Gaebel W, Benkert O. Pramipexole, a dopamine agonist, in major depression. antidepressant effects and tolerability in an open-label study with multiple doses. Clin Neuropharmacol 1997; 20:S36-S45.
11. Kasper S, Barnas C, Heiden A et al. Pramipexole as adjunct to haloperidol in schizophrenia. Safety Efficacy Eur Neuropsychopharmacol 1997; 7: 65-70.
12. Willner P, Lappas S, Cheeta S, Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology 1994; 115: 454-462.
13. Rosenbaum JF, Fredman SJ. Pramipexole treatment for cocaine cravings. Am J Psychiatry 1999; 156: 1834.
14. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65.
15. Sporn J, Ghaemi SN, Sambur MR et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000; 12: 137-140.
16. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry 1999; 156: 798.
17. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology the Fourth Generation of Progress, 4th edn. Philadelphia, MD: Lippincott-Raven Healthcare, 1995: 1081-1097.
18. Maier W, Philipp M, Heuser I, Schlegel S, Buller R, Wetzel H. Improving depression severity assessment - I. Reliability, internal validity and sensitivity to change of three observer depression scales. J Psychiatr Res 1988; 22: 3-12.
19. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology (Revised). Rockville MD: US Department Health, Education, and Welfare Publication (ADM: National Institute of Mental Health; 1976: 76-338.
20. Garvey CA, Gross D, Freeman L. Assessing psychotropic medication side effects among children. A reliability study. J Child Adolesc Psychiatr Ment Health Nurs 1991; 4: 127-131.
21. Gibbons RD, Hedeker D, Elkin I et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50: 739-750.
22. SAS/STAT. STAT Software. Version 7.0. Cary, NC: SAS Institute, 1998.
23. Boerlin HL, Gitlin MJ, Zoellner LA, Hammen CL. Bipolar depression and antidepressant-induced mania: a naturalistic study. J Clin Psychiatry 1998; 59: 374-379.
24. Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord 1997; 46: 73-77.
25. Benkert O, Grunder G, Wetzel H. Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 1992; 25: 254-260.
26. Mouret J, Lemoine P, Minuit MP. Polygraphic, clinical and therapeutic markers of dopamine-dependent depressions. C R Acad Sci III 1987; 305: 301-306.
27. Sonawalla SB, Spillmann MK, Kolsky AR et al. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry 1999; 60: 580 583.